India, March 20 -- Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, has announced the launch of India's only vertically integrated, purpose-designed Cell & Gene Therapy (CGT) Infrastructure & Viral Vector Production Facility at Genome Valley, expanding its expertise from vaccine innovation to leading-edge regenerative and personalised therapies that promise hope for millions.

This facility ushers in a new era of gene and cell therapies to tackle scientific challenges such as targeted gene expression, immune system modulation, and long-term cell survival.

The work will span from boosting immune responses against cancer to ensuring that therapeutic proteins are safely a...